This trial is looking at whether or not a new drug, efavaleukin alfa, can help people with UC achieve clinical remission. Participants will be randomly assigned to receive either the drug or a placebo, and the effects will be monitored over the course of 12 weeks. There is also the option to enter an exploratory long-term treatment period for up to 52 weeks total.
1 Primary · 6 Secondary · Reporting Duration: Up to 58 weeks
320 Total Participants · 6 Treatment Groups
Primary Treatment: Efavaleukin alfa · Has Placebo Group · Phase 2
Age 18 - 80 · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
|18 - 65||100.0%|
|Atlanta Gastroenterology Associates||100.0%|